SI-BONE IncSIBN
SIBN
About: SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
Employees: 349
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1,276% more call options, than puts
Call options by funds: $908K | Put options by funds: $66K
100% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 17
53% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 38
10% more funds holding
Funds holding: 143 [Q4 2024] → 158 (+15) [Q1 2025]
2% more capital invested
Capital invested by funds: $558M [Q4 2024] → $567M (+$9.28M) [Q1 2025]
0.37% more ownership
Funds ownership: 94.91% [Q4 2024] → 95.28% (+0.37%) [Q1 2025]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$22
24%
upside
Avg. target
$24
34%
upside
High target
$25
41%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Truist Securities Samuel Brodovsky | 24%upside $22 | Buy Maintained | 6 May 2025 |
Cantor Fitzgerald Ross Osborn | 41%upside $25 | Overweight Reiterated | 6 May 2025 |
Needham David Saxon | 36%upside $24 | Buy Reiterated | 6 May 2025 |
Financial journalist opinion
Based on 3 articles about SIBN published over the past 30 days
Neutral
GlobeNewsWire
23 hours ago
SI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025
SANTA CLARA, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, August 12, 2025, at 12:00 p.m. Pacific Time/03:00 p.m. Eastern Time.
Neutral
GlobeNewsWire
2 weeks ago
SI-BONE To Report Second Quarter 2025 Financial Results on August 4, 2025
SANTA CLARA, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the second quarter of 2025 after market close on Monday, August 4, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Positive
Zacks Investment Research
3 weeks ago
All You Need to Know About Si-Bone (SIBN) Rating Upgrade to Buy
Si-Bone (SIBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
GlobeNewsWire
1 month ago
SI-BONE to Truist Securities MedTech Conference on June 17, 2025
SANTA CLARA, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Truist Securities MedTech Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, June 17, 2025, at 10:00 a.m. Pacific Time/1:00 p.m. Eastern Time.
Neutral
GlobeNewsWire
1 month ago
SI-BONE to Present at Truist Securities MedTech Conference on June 17, 2025
SANTA CLARA, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Truist Securities MedTech Conference in Boston, MA.
Neutral
GlobeNewsWire
2 months ago
SI-BONE to Present at Goldman Sachs 46th Global Healthcare Conference on June 10, 2025
SANTA CLARA, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Goldman Sachs 46th Global Healthcare Conference in Miami Beach, FL. Management will be hosting a fireside chat on Tuesday, June 10, 2025, at 8:20 a.m. Pacific Time/11:20 a.m. Eastern Time.
Positive
Zacks Investment Research
2 months ago
Wall Street Analysts See a 34.22% Upside in Si-Bone (SIBN): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 34.2% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
MarketBeat
2 months ago
4 Recent Earnings Winners Riding Fresh Momentum in May
The market turbulence in 2025 has sent stocks zig-zagging up and down. Despite the unavoidable impact of political developments on share price performance, some companies have seen major gains based on a more traditional driver of motion: strong earnings reports.
Positive
Zacks Investment Research
2 months ago
What Makes Si-Bone (SIBN) a Strong Momentum Stock: Buy Now?
Does Si-Bone (SIBN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Positive
Zacks Investment Research
2 months ago
Wall Street Analysts Think Si-Bone (SIBN) Could Surge 41.21%: Read This Before Placing a Bet
The consensus price target hints at a 41.2% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Charts implemented using Lightweight Charts™